Discontinued — last reported Q2 '18
Other
Fair Value Measurement Disclosure
Pfizer Fair Value Measurement Disclosure remained flat by 0.0% to $590.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 478.4%, from $102.00M to $590.00M.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ3 2015
Last reportedQ2 2018
How to read this metric
Higher levels indicate a larger portion of the balance sheet is subject to market-based valuation volatility.
Detailed definition
This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring o...
Peer comparison
Standard disclosure for financial institutions with significant investment holdings.
Metric ID:
fair_value_measurement_disclosureHistorical Data
5 periods
| Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|
| Value | $102.00M | $102.00M | $0.00 | $590.00M | $590.00M |
| QoQ Change | — | +0.0% | -100.0% | — | +0.0% |
| YoY Change | — | — | — | +478.4% | +478.4% |
Range$0.00 – $590.00M
CAGR+478.4%
Avg YoY Growth+478.4%
Median YoY Growth+478.4%
Current Streak2 quarters growth
Fair Value Measurement Disclosure at Other Companies
Frequently Asked Questions
- What is Pfizer's fair value measurement disclosure?
- Pfizer (PFE) reported fair value measurement disclosure of $590.00M in Q3 2025.
- How has Pfizer's fair value measurement disclosure changed year-over-year?
- Pfizer's fair value measurement disclosure increased by 478.4% year-over-year, from $102.00M to $590.00M.
- What does fair value measurement disclosure mean?
- The total value of assets and liabilities reported at current market prices.